

NOTE: This bill has been prepared for the signatures of the appropriate legislative officers and the Governor. To determine whether the Governor has signed the bill or taken other action on it, please consult the legislative status sheet, the legislative history, or the Session Laws.



SENATE BILL 24-124

BY SENATOR(S) Michaelson Jenet and Rich, Buckner, Cutter, Exum, Ginal, Gonzales, Hansen, Hinrichsen, Kirkmeyer, Kolker, Marchman, Mullica, Pelton B., Pelton R., Priola, Roberts, Will, Winter F., Fenberg; also REPRESENTATIVE(S) Hartsook and Duran, Bird, Boesenecker, Brown, English, Hamrick, Jodeh, Kipp, Lieder, Lindsay, Lukens, McCormick, McLachlan, Rutinel, Titone, McCluskie.

CONCERNING REQUIRING HEALTH-CARE COVERAGE FOR BIOMARKER TESTING.

Be it enacted by the General Assembly of the State of Colorado:

SECTION 1. In Colorado Revised Statutes, 10-16-104, **add** (28) as follows:

10-16-104. Mandatory coverage provisions - definitions - rules.
(28) **Biomarker testing.** (a) ALL LARGE GROUP HEALTH BENEFIT PLANS AND, TO THE EXTENT THAT SUCH COVERAGE IS NOT IN ADDITION TO THE BENEFITS PROVIDED PURSUANT TO THE BENCHMARK PLAN, ALL INDIVIDUAL AND SMALL GROUP HEALTH BENEFIT PLANS SHALL PROVIDE COVERAGE FOR BIOMARKER TESTING PURSUANT TO THIS SUBSECTION (28).

Capital letters or bold & italic numbers indicate new material added to existing law; dashes through words or numbers indicate deletions from existing law and such material is not part of the act.

(b) COVERAGE MUST INCLUDE BIOMARKER TESTING FOR DIAGNOSIS, TREATMENT, APPROPRIATE MANAGEMENT, AND ONGOING MONITORING OF A COVERED PERSON'S DISEASE OR CONDITION TO GUIDE TREATMENT DECISIONS WHEN THE TEST IS SUPPORTED BY MEDICAL AND SCIENTIFIC EVIDENCE, INCLUDING:

(I) LABELED INDICATIONS FOR AN FDA-APPROVED OR FDA-CLEARED TEST;

(II) INDICATED TESTS FOR AN FDA-APPROVED DRUG;

(III) WARNINGS AND PRECAUTIONS ON FDA-APPROVED DRUG LABELS;

(IV) CENTERS FOR MEDICARE AND MEDICAID SERVICES NATIONAL COVERAGE DETERMINATIONS OR MEDICARE ADMINISTRATIVE CONTRACTOR LOCAL COVERAGE DETERMINATIONS; OR

(V) NATIONALLY RECOGNIZED CLINICAL PRACTICE GUIDELINES, CONSENSUS STATEMENTS, AND PEER-REVIEWED STUDIES.

(c) THE COVERAGE REQUIRED BY THIS SUBSECTION (28) IS SUBJECT TO ANNUAL DEDUCTIBLES, COPAYMENTS, OR COINSURANCE REQUIREMENTS UNDER THE HEALTH BENEFIT PLAN BUT IS NOT SUBJECT TO ANY ANNUAL OR LIFETIME MAXIMUM BENEFIT LIMIT.

(d) THE COVERAGE REQUIRED BY THIS SUBSECTION (28) MUST BE PROVIDED IN A MANNER THAT LIMITS UNREASONABLE DISRUPTIONS IN CARE, INCLUDING LIMITING THE NEED FOR MULTIPLE BIOPSIES OR BIOSPECIMEN SAMPLES.

(e) NOTHING IN THIS SUBSECTION (28) SHALL BE CONSTRUED TO REQUIRE COVERAGE FOR BIOMARKER TESTING FOR SCREENING PURPOSES.

(f) A CARRIER MAY REQUIRE PRIOR AUTHORIZATION FOR BIOMARKER TESTING IN THE SAME MANNER THAT PRIOR AUTHORIZATION IS REQUIRED FOR ANY OTHER COVERED BENEFIT AND CONSISTENT WITH SECTION 10-16-112.5.

(g) (I) WITHIN ONE HUNDRED TWENTY DAYS AFTER THE EFFECTIVE

DATE OF THIS SUBSECTION (28), THE DIVISION SHALL SUBMIT TO THE FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES:

(A) A DETERMINATION AS TO WHETHER THE BENEFIT SPECIFIED IN THIS SUBSECTION (28) IS IN ADDITION TO ESSENTIAL HEALTH BENEFITS AND WOULD BE SUBJECT TO DEFRAID BY THE STATE PURSUANT TO 42 U.S.C. SEC. 18031 (d)(3)(B); AND

(B) A REQUEST THAT THE FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES CONFIRM THE DIVISION'S DETERMINATION WITHIN SIXTY DAYS AFTER RECEIPT OF THE DIVISION'S REQUEST AND SUBMISSION OF ITS DETERMINATION.

(II) THIS SUBSECTION (28) APPLIES TO, AND THE DIVISION SHALL IMPLEMENT THE PROVISIONS OF THIS SUBSECTION (28) FOR, LARGE EMPLOYER HEALTH BENEFIT PLANS ISSUED OR RENEWED IN THIS STATE ON OR AFTER JANUARY 1, 2025.

(III) THIS SUBSECTION (28) APPLIES TO, AND THE DIVISION SHALL IMPLEMENT THE REQUIREMENTS OF THIS SUBSECTION (28) FOR, INDIVIDUAL AND SMALL GROUP HEALTH BENEFIT PLANS ISSUED OR RENEWED IN THIS STATE TWELVE MONTHS AFTER THE EARLIER OF THE FOLLOWING:

(A) THE DIVISION RECEIVES CONFIRMATION FROM THE FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES THAT THE COVERAGE SPECIFIED IN THIS SUBSECTION (28) DOES NOT CONSTITUTE AN ADDITIONAL BENEFIT THAT REQUIRES DEFRAID BY THE STATE PURSUANT TO 42 U.S.C. SEC. 18031 (d)(3)(B);

(B) THE FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES HAS OTHERWISE INFORMED THE DIVISION THAT THE COVERAGE DOES NOT REQUIRE STATE DEFRAID PURSUANT TO 42 U.S.C. SEC. 18031 (d)(3)(B); OR

(C) MORE THAN THREE HUNDRED SIXTY-FIVE DAYS HAVE PASSED SINCE THE DIVISION SUBMITTED ITS DETERMINATION AND REQUEST FOR CONFIRMATION THAT THE COVERAGE SPECIFIED IN THIS SUBSECTION (28) IS NOT AN ADDITIONAL BENEFIT THAT REQUIRES STATE DEFRAID PURSUANT TO 42 U.S.C. SEC. 18031 (d)(3)(B), AND THE FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES HAS FAILED TO RESPOND TO THE REQUEST WITHIN THAT PERIOD, IN WHICH CASE THE DIVISION SHALL CONSIDER THE

FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES' UNREASONABLE DELAY A PRECLUSION FROM REQUIRING DEFRAIAL BY THE STATE.

(h) THE COMMISSIONER SHALL IMPLEMENT THIS SUBSECTION (28) AND SHALL ADOPT RULES CONSISTENT WITH AND AS ARE NECESSARY TO IMPLEMENT THIS SUBSECTION (28).

(i) AS USED IN THIS SUBSECTION (28):

(I) "BIOMARKER" MEANS A CHARACTERISTIC THAT IS OBJECTIVELY MEASURED AND EVALUATED AS AN INDICATOR OF NORMAL BIOLOGICAL PROCESSES, PATHOGENIC PROCESSES, OR PHARMACOLOGIC RESPONSES TO A SPECIFIC THERAPEUTIC INTERVENTION, INCLUDING KNOWN GENE-DRUG INTERACTIONS FOR MEDICATIONS BEING CONSIDERED FOR USE OR ALREADY BEING ADMINISTERED. "BIOMARKER" INCLUDES GENE MUTATIONS, CHARACTERISTICS OF GENES, OR PROTEIN EXPRESSION.

(II) "BIOMARKER TESTING" MEANS THE ANALYSIS OF A PATIENT'S TISSUE, BLOOD, OR OTHER BIOSPECIMEN FOR THE PRESENCE OF A BIOMARKER. "BIOMARKER TESTING" INCLUDES SINGLE-ANALYTE TESTS, MULTIPLEX PANEL TESTS, PROTEIN EXPRESSION, AND WHOLE EXOME, WHOLE GENOME, AND WHOLE TRANSCRIPTOME SEQUENCING. "BIOMARKER TESTING" DOES NOT INCLUDE DIRECT-TO-CONSUMER GENETIC TESTS.

(III) "CONSENSUS STATEMENTS" MEANS STATEMENTS DEVELOPED BY AN INDEPENDENT, MULTIDISCIPLINARY PANEL OF EXPERTS UTILIZING A TRANSPARENT METHODOLOGY AND REPORTING STRUCTURE AND WITH A CONFLICT OF INTEREST POLICY. CONSENSUS STATEMENTS ARE DEVELOPED FOR SPECIFIC CLINICAL CIRCUMSTANCES AND ARE BASED ON THE BEST AVAILABLE EVIDENCE FOR THE PURPOSE OF OPTIMIZING THE OUTCOMES OF CLINICAL CARE.

(IV) "NATIONALLY RECOGNIZED CLINICAL PRACTICE GUIDELINES" MEANS EVIDENCE-BASED CLINICAL PRACTICE GUIDELINES DEVELOPED BY INDEPENDENT ORGANIZATIONS OR MEDICAL PROFESSIONAL SOCIETIES UTILIZING A TRANSPARENT METHODOLOGY AND REPORTING STRUCTURE AND WITH A CONFLICT OF INTEREST POLICY. CLINICAL PRACTICE GUIDELINES:

(A) ESTABLISH STANDARDS OF CARE INFORMED BY A SYSTEMATIC REVIEW OF EVIDENCE AND AN ASSESSMENT OF THE BENEFITS AND RISKS OF

ALTERNATIVE CARE OPTIONS; AND

(B) INCLUDE RECOMMENDATIONS INTENDED TO OPTIMIZE PATIENT CARE.

SECTION 2. Safety clause. The general assembly finds, determines, and declares that this act is necessary for the immediate preservation of the public peace, health, or safety or for appropriations for

the support and maintenance of the departments of the state and state institutions.

Steve Fenberg
PRESIDENT OF
THE SENATE

Julie McCluskie
SPEAKER OF THE HOUSE
OF REPRESENTATIVES

Cindi L. Markwell
SECRETARY OF
THE SENATE

Robin Jones
CHIEF CLERK OF THE HOUSE
OF REPRESENTATIVES

APPROVED _____
(Date and Time)

Jared S. Polis
GOVERNOR OF THE STATE OF COLORADO